Acute Cardiovascular Effects of Sibutramine in Conscious Rats

Journal of Pharmacology and Experimental Therapeutics

Volumn 308, Issue 3, 2004, Pages 1102-1110

  Woolard, Jeanette ^a   Bennett, Terence ^a   Dunn, William R ^a   Heal, David J ^b   Aspley, Susan ^c   Gardiner, Sheila M ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b RenaSci Ltd   (United Kingdom)

^c ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [1 (4 CHLOROPHENYL)CYCLOBUTYL] 3 METHYL 1 METHYLAMINOBUTANE; 1 AMINO 1 [1 (4 CHLOROPHENYL)CYCLOBUTYL] 3 METHYLBUTANE; ALPHA ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; NORADRENALIN; NORADRENALIN TRANSPORTER; NORADRENALIN UPTAKE INHIBITOR; PHENTOLAMINE; PROPRANOLOL; SEROTONIN UPTAKE INHIBITOR; SIBUTRAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL TONE; CARDIOVASCULAR EFFECT; CELIAC ARTERY; CONCENTRATION RESPONSE; MALE; MESENTERIC ARTERY; NONHUMAN; OBESITY; PRESSOR RESPONSE; PRIORITY JOURNAL; RAT; TACHYCARDIA; VASOCONSTRICTION; VASODILATATION;

ANIMALS; ANTIHYPERTENSIVE AGENTS; APPETITE DEPRESSANTS; CARDIOVASCULAR SYSTEM; CYCLOBUTANES; DRUG INTERACTIONS; HEMODYNAMIC PROCESSES; NOREPINEPHRINE; PHENTOLAMINE; PROPRANOLOL; RATS; RATS, SPRAGUE-DAWLEY;

EID: 1342323321     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.103.061259     Document Type: Article

References (35)

1. Birkenfeld AL, Schroeder CS, Boschmann M, Tank J, Franke G, Luft FC, Biaggioni I, Sharma AM, and Jordan J (2002) Paradoxical effect of sibutramine on autonomic cardiovascular function. Circulation 106:2459-2465.
2. Buhler FR, Laragh JH, Baer L, Vaughan ED Jr., and Brunner HR (1972) Propranolol inhibition of renin secretion. A specific approach to diagnosis and treatment of renin-dependent hypertensive diseases. New Engl J Med 287:1209-1214.
3. 3H]noradrenaline uptake and effect of DSP-4 lesioning and antidepressant treatments. Neuropharmacology 35:63-70.
4. Clapham JC, Arch JRS, and Tadayyon M (2001) Anti-obesity drugs: a critical review of current therapies and future opportunities. Pharmacol Ther 89:81-121.
5. Connoley IP, Liu Y-L, Frost I, Reckless IP, Heal DJ, and Stock MJ (1999) Thermogenic effects of sibutramine and its metabolites. Br J Pharmacol 126:1487-1495.
6. G-nitro-L-arginine methyl ester: methodological considerations for studies of small arteries. J Hypertens 13:1217-1221.
7. Dunn WR, Wallis SJ, and Gardiner SM (1998) Remodelling and enhanced myogenic tone in cerebral resistance arteries isolated from genetically hypertensive Brattleboro rats. J Vasc Res 35:18-26.
8. Fantino M and Souquet AM (1995) Effects of metabolite 1 and 2 of sibutramine on the short-term control of food intake in the rat. Int J Obes 19:145.
9. Fujioka K, Seaton TB, and Rowe E (2000) Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus. Diab Obes Metab 2:175-187.
10. Gardiner SM and Bennett T (1988) Regional hemodynamic responses to adrenoceptor antagonism in conscious rats. Am J Physiol 255:H813-H824.
11. Gardiner SM, Compton AM, Kemp PA, Bennett T, Bose C, Foulkes R, and Hughes B (1990) Antagonist effects of human α-CGRP [8-37] on the in vivo regional haemodynamic actions of human α-CGRP. Biochem Biophys Res Commun 171:938-943.
12. G-nitro-L-arginine methyl ester on vasodilator responses to acetylcholine, 5′-N-ethylcarboxamidoadenosine or salbutamol in conscious rats. Br J Pharmacol 103:1725-1732.
13. Gardiner SM, Kemp PA, March JE, and Bennett T (1993) Regional haemodynamic effects of angiotensin II (3-8) in conscious rats. Br J Pharmacol 110:159-162.
14. Gardiner SM, March JE, Kemp PA, and Bennett T (2002) Complex regional haemodynamic effects of anandamide in conscious rats. Br J Pharmacol 135:1889-1896.
15. Goldberg NR, Beuming T, Soyer OS, Goldstein RA, Weinstein H, and Javitch JA (2003) Probing conformational changes in neurotransmitter transporters: a structural context. Eur J Pharmacol 479:3-12.
16. Guimaraes S and Moura D (2001) Vascular adrenoceptors: an update. Pharmacol Rev 53:319-356.
17. Halford JCG, Wanninayake SCD, and Blundell JE (1998) Behavioural satiety sequence (BSS) for the diagnosis of drug action on food intake. Pharmacol Biochem Behav 61:159-168.
18. Halpern W, Osol G, and Coy GS (1984) Mechanical behavior of pressurized in vitro prearteriolar vessels determined with a video system. Ann Biomed Eng 12:463-479.
19. Heal DJ and Cheetham SC (1997) The pharmacology of sibutramine, the first serotonin and noradrenaline reuptake inhibitor to be developed for the treatment of obesity. Lett Pharmacol 11 (Suppl 10):3-8.
20. Hind ID, Mangham JE, Ghani SP, Haddock RE, Garratt CJ, and Jones RW (1999) Sibutramine pharmacokinetics in young and elderly healthy subjects. Br J Clin Pharmacol 54:847-849.
21. Jackson HC, Needham AM, Hutchins LJ, Mazurkiewicz SE, and Heal DJ (1997) Comparison of the effects of sibutramine and other monoamine reuptake inhibitors on food intake in the rat. Br J Pharmacol 121:1758-1762.
22. Janssen PJJM, Gardiner SM, Compton AM, and Bennett T (1991) Mechanisms contributing to the differential haemodynamic effects of bombesin and cholecystokinin in conscious, Long-Evans rats. Br J Pharmacol 102:123-134.
23. King DJ and Devaney N (1988) Clinical pharmacology of sibutramine hydrochloride (BTS 54524), a new antidepressant, in healthy volunteers. Br J Clin Pharmacol 26:607-611.
24. Kissebah AH and Krakower GR (1994) Regional adiposity and morbidity. Physiol Rev 74:761-811.
25. Kopelman PG (2000) Obesity as a medical problem. Nature (Lond) 404:635-643.
26. Luque CA and Rey JA (2002) The discovery and status of sibutramine as an antiobesity drug. Eur J Pharmacol 440:119-128.
27. Luscombe GP, Hopcroft RH, Thomas PC, and Buckett WR (1989) The contribution of metabolites to the rapid and potent down-regulation of rat cortical β-adrenoceptors by the putative antidepressant, sibutramine hydrochloride. Neuropharmacology 28:129-134.
28. Luscombe GP, Slater NA, Lyons MB, Wynne RD, Scheinbaum ML, and Buckett WR (1990) Effect on radiolabelled-monoamine uptake in vitro of plasma taken from healthy volunteers administered the antidepressant sibutramine HCl. Psychopharmacology 100:345-349.
29. Rowley HL, Butler SA, Prow MR, Dykes SG, Aspley S, Kilpatrick IC, and Heal DJ (2000) Comparison of the effects of sibutramine and other weight-modifying drugs on extracellular dopamine in the nucleus accumbens of freely moving rats. Synapse 38:167-176.
30. Schroeder C, Tank J, Boschmann M, Diedrich A, Sharma AM, Baggioni I, Luft C, and Jordan J (2002) Selective norepinephrine reuptake inhibition as a human model of orthostatic intolerance. Circulation 105:347-353.
31. Stock MJ (1997) Sibutramine: a review of the pharmacology of a novel anti-obesity agent. Int J Obes 21:S25-S29.
32. Tank J, Schroeder C, Diedrich A, Szczech E, Haertter S, Sharma AM, Luft F, and Jordan J (2003) Selective impairment in sympathetic vasomotor control with norepinephrine transporter inhibition. Circulation 107:2949-2954.
33. Theodorsson-Norheim E (1987) Friedman and Quade tests: BASIC computer program to perform nonparametric two-way analysis of variance and multiple comparisons on ranks of several related samples. Comput Biol Med 17:85-99.
34. Woolard J, Gardiner SM, Aspley S, and Bennett T (2001) Regional haemodynamic responses to fluoxetine or nisoxetine in conscious Sprague-Dawley rats. Br J Pharmacol 133 (Suppl):27P.
35. Woolard J, Gardiner SM, Aspley S, and Bennett T (2002) Regional haemodynamic effects of the 5-HT and noradrenaline re-uptake inhibitor, sibutramine, in conscious rats: effects of α or β-adrenoceptor antagonism. Br J Pharmacol 137 (Suppl):76P.